{"name":"Brainstorm-Cell Therapeutics","slug":"brainstorm-cell-therapeutics","ticker":"","exchange":"","domain":"","description":"Brainstorm-Cell Therapeutics is a clinical-stage biotechnology company focused on the development of adult stem cell-based therapies for neurodegenerative diseases. The company's lead product, NurOwn (Debamestrocel - MSC-NTF), is in Phase 3 clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS).","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NurOwn® (MSC-NTF cells)","genericName":"NurOwn® (MSC-NTF cells)","slug":"nurown-msc-ntf-cells","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_3"}]}],"pipeline":[{"name":"NurOwn® (MSC-NTF cells)","genericName":"NurOwn® (MSC-NTF cells)","slug":"nurown-msc-ntf-cells","phase":"phase_3","mechanism":"NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS).","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNN2lTNUN3VFhqS09wZ2N0Q0FNY2x3dTlSaGlBV3A2d00zbUs0RnVoLVIxYmM3UWRRU1Q4ZmhQT0hnR0k5NWJPTHJ1SXJIMy1HSi1rR0JVN0stM01ZS1oxNzI1UzlFYklGdGR2WXJHaVFTdFlKQUtBdXhQbGtUQnh2WlpWYmgyRmxBTFdrU3YzbU1FZGpvWjhtejdoU1J1MFNq?oc=5","date":"2026-03-10","type":"pipeline","source":"openPR.com","summary":"Cell and Gene Therapies in Rare Disorders Market Size in the US - openPR.com","headline":"Cell and Gene Therapies in Rare Disorders Market Size in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQRGZldzAtV3FRTlkyY2xWSFhTeTR5blI0YVdEWk5paldEZjM2alE3YUdPd3V3RGlZaU96ampaRE1kMHc0VHRyY3VraFNEZ2xIaUZtQ1FQTTdPMmxnelNQbENZbkwxZ1VWZFNrVHFnUWtUQUh5aUNSVkswQWFwNmU5SjlJaFdJcWRvRDRwYUV2elVvM2c1V1JRUFlBRGR2QmF4dEE2bTdfMHJyRExRX2dyMXdYUTBYd2U4UHE0dEZWa281cFV1TXdtWGV1OXFndDJGbXpRUFlhTTZKVldTR0JiVG1VR0FNa281eF9sRzlGeWRhaHpIRzhOVEc4VQ?oc=5","date":"2026-02-26","type":"pipeline","source":"PR Newswire","summary":"Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February - PR Newswire","headline":"Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNLWFDNzZITGJvSVNCbTQwREwtQXVoaUxRVVJXZWZxN3RkNXBhRXVfM3JDVkRXS1d0SlhnNnQyV0Rabzh4TG9FRUZYeVpwcVZOUklZNzYtVFc5Y2x6bFFVWUNNcUVKVjF1UktMSmtwU1FjSmtMVUE0dWRnR0YtdWNwM2M2V1JYVklWcFVOVkFXejQ4WDZ3bHJlMFFFbmRaaVFfUmZoWm1uMTlBNHRWY21hd0UxR1hzeEJEU0c1S3hDUXNqUlA1dnNmZ21DVU5HaldLOU5uM2ZNd3R6MEZDS3c?oc=5","date":"2026-02-20","type":"pipeline","source":"PR Newswire","summary":"Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - PR Newswire","headline":"Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV19SSmJGenRyTUxPR0twOHlwei1YNTVYUWNYVi1NaGoxU3NpYUdLQjNpamFnR3lKN3JXelRkeHdFWWdDeGRHUkg4YmNkcHFjLWhUNDJlVW5fX0xtQW1VUnVVdHA0d1l2X3RhTDNmUHJqUl9UUTJqZEpBVzdhLTI5SEVsS3lsODNxUG04OWdfUDE4T0hvMk9xUkVqaVNPd0dSOTMxb3U4YTZXTEttQ280SXRvek1uekJfVmZLYTFJWERNYkhoX0hyaWxHMm1Zcl9jcW1fekFyZ3I3MzNWbjlFVThCZG5aMHNDV1I3czZyZ19QZGR2cmlaNXJFSE9KVV9TejdEYXZaUEN3S1ZMNkNnR0JLSnFabXJMY3RIZmttTWx1MXVmZ0hLS0MwdE9aU2lxR2ZwajlqMG9mRzhFSEgwUw?oc=5","date":"2025-12-09","type":"pipeline","source":"PR Newswire","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPaUpjZWVBaHRGWXRIZ3Zibk1KT0pHaTNlUFd2aVhvaHZmSGFBcVBPeDVIdGQ1M2oyRVNWQ21wSVNqOXZseVNTX1lwU0lZcE9tbFVKVHlvVTUybzFiOFdHc1lialNhYXVmTHNzTHFRZGxRS1N3M2UzdUNDeXZvR3ZwTGJkdk1iaXJSWkVzT3NVZkUzWmJBM00tZEtuclVNMk52NUJqN1RGbjhCMjh1VmRRUmMtVElCZGtFZVI0UHd2bW81NmZjR3ZXZkZJY0JhWUtQZ0ZsbnpIbW11Q3BtQkhJeVhlQ1gwNFFlT2pzTFdZbVhJV3hkQTFVUktYQWdmSUJTSzdvbUFYT1Y1aW5UUHdEUW1jNy0wRU9Zb1R2MzJYNHZaeDhQODlYQkRDUG9kcExoa0dzWUxESktqY0hEMkZFQTVHQzJ2aGdKdURJUzNhMzA?oc=5","date":"2025-10-09","type":"regulatory","source":"Business Wire","summary":"Mesenchymal Stem Cells/Medicinal Signaling Cells Advances & Applications Report 2025: 1,670+ Trials, 12 Approvals Worldwide, and Path to 50 Approvals by 2040 - ResearchAndMarkets.com - Business Wire","headline":"Mesenchymal Stem Cells/Medicinal Signaling Cells Advances & Applications Report 2025: 1,670+ Trials, 12 Approvals Worldw","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQYmtyV3JOSE1tU19HWE1HQzgwRVhwYkJNUG1iLS1lQmtONW9BNGhFWDFUNmJVVW1ObU5ZYjhBZHExaDg5bjdtZjRvbERUbFdwVWU2NFZNWDdxbG1VVnVtZzFZUTMwa3d5UkMxZndxYWE5dHpNanJwUi1uTThCei1QNDhmX0JPWHhONV90bmhSazMtX1lDb0pzN2NRbTBpaUVoRTVBYXg3YkZ3SHVlZnRIZXVaRUtDZGNmUFlpTkpVY0hSSF80RjhKMVFUTVctelBNMGEtZVJTbk40Z251Vy13akJRRktuNU5qN3BrdjZmVlFHVnl4YnFNQ251cmc1Z01ha1M0REdKX29rYU02dFE?oc=5","date":"2025-07-24","type":"pipeline","source":"PR Newswire UK","summary":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight - PR Newswire UK","headline":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5hWG8zRFRObHp4SURUdENRS1pIRVBkdU5LOWp1cmwyTzk4ZlNELWhleTJkTHh3ak9yVlJnMDF2WDRDeGJ4N1pBY2E5elZEMkNVZlI4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"BCLI Stock Price, News & Analysis | Brainstorm Cell Therapeutics I - Stock Titan","headline":"BCLI Stock Price, News & Analysis | Brainstorm Cell Therapeutics I","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQbVladVBMRXRrZzAydEx1bWR0bURJeXBCbFh4UkJHb1ZZX1JYa3NzWlpSRGFvUnpXWVM4cmtoR25QQXR2TGlKTjhfTjY3NlZON0tyUVBxYy16MVJMcGdlLWFaUUJ3eVE1c2Rid1ZQc2NmbnMzdmRDTldxb2hCZmsyOUw2Ti1UMy1iNVlBbGpFWF9qeTJvMnQwQm9YRnBVOXFBeWE3c2ZoaC00M1o2WnBMQm1ZRGMxUExVdUw2WFRiMHBzc0xNMU40c3VFX3QtU291X1NnQmlkYTVrX1YyX3R6RkdBZFo5RzU4Z0ZXUzBILWtGcmJXbU4ydVJnTklzOC0tS3ZfTFloWWdfNm9wcFdMVWhaRmJ2VE1IdXgzUzh2cjAzS1Y1?oc=5","date":"2025-02-21","type":"pipeline","source":"GlobeNewswire","summary":"Cell and Gene Therapies in Rare Disorders Market to - GlobeNewswire","headline":"Cell and Gene Therapies in Rare Disorders Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNY3NIZkNORGtuRkpVT0lMbzlBOEFycGRGTkdIeHhxTFIzYUQyM2U2WkdVSjBhQlc5ZnFvNDZjNjRQUUk2aTRVZUFOUjU3SU85eVRfemtiQVdtNURlLTJQVF9kcWNUczJ1QlVKNmNaaGdvNzlKQjlra1NZRk5QMHp5NnVzaFF0aTA1N3VxdTFQMFBWWVI2YkF5QnpDZE1nLXhBQ0tZLTltdlhCRzZUSFI1R1BIZmlScTNZYUVaNFFPc3Y0Z3Qt?oc=5","date":"2024-06-20","type":"pipeline","source":"BioSpace","summary":"BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer - BioSpace","headline":"BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOUzdzVFMtVXJCczVQNFlzUFJfandBWnc0MG9HSHJMa1VSQ3N2cDJYMVczeDJPQVJwMy1ueDdDeVVkbXc4NV9zaW9DT2JBNGdIemQyQjBWRVNtSWl1Z05iSFF6bllucUVzXzN1SG55T3p4U2ZGZXZES2xMekxMNEZUMFkyVFJ3UHVvQ2Z4SUlla0lXanU0RmxHZTA5dXZLdw?oc=5","date":"2023-09-25","type":"regulatory","source":"BioPharma Dive","summary":"FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show - BioPharma Dive","headline":"FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPdW1pWWg1Z1p1ampYZzdSSnd3eFRkMDdmc1lQNl9xR0M3QWhBOGdKR05HWXRIbDhtZ0hVWllZWDZjUG02WU1BNy1VWXY4LXAyMGZIMGV4WkNsZVlxYk5mQ2NMUmJBRnlBckJ2X3c1ZXJhNGh0Q0NoU0tmeUVSbnhidHVITWp4cGtCSi1Gbkk2Qzg3R21wc0dGS0QwZ1hMcm9KaG0xX2lUNA?oc=5","date":"2022-11-11","type":"regulatory","source":"BioPharma Dive","summary":"FDA declines to review Brainstorm’s ALS therapy - BioPharma Dive","headline":"FDA declines to review Brainstorm’s ALS therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE10SHZDLUQ3M3R4QUhGUHB5M1Y0cnpxT0h1SlA4T0hkcUM0c2pYb1NKWWdjRVREZWd1VkxEYWNDU05RMDV2bUhvUEppcS1mRjBnbXc?oc=5","date":"2017-05-08","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}